Sangamo Therapeutics, Inc. (SGMO)
NASDAQ: SGMO · Real-Time Price · USD
0.8200
-0.0373 (-4.35%)
At close: Mar 28, 2025, 4:00 PM
0.8186
-0.0014 (-0.17%)
After-hours: Mar 28, 2025, 7:55 PM EDT
Sangamo Therapeutics Employees
Sangamo Therapeutics had 183 employees as of December 31, 2024. The number of employees decreased by 222 or -54.81% compared to the previous year.
Employees
183
Change (1Y)
-222
Growth (1Y)
-54.81%
Revenue / Employee
$315,847
Profits / Employee
-$535,197
Market Cap
184.26M
Employees Chart
SGMO News
- 11 days ago - Sangamo Therapeutics, Inc. (SGMO) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 11 days ago - Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results - Business Wire
- 22 days ago - Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference - Business Wire
- 7 weeks ago - Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile - Business Wire
- 2 months ago - Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sangamo Therapeutics, Inc. (SGMO) And Encourages Shareholders to Reach Out - Accesswire
- 2 months ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Shareholders to Learn More About the Investigation - Accesswire
- 2 months ago - Sangamo Therapeutics, Inc. (SGMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - Accesswire
- 2 months ago - Bronstein, Gewirtz & Grossman, LLC Encourages Sangamo Therapeutics, Inc. (SGMO) Shareholders to Inquire about Securities Investigation - Accesswire